Alexion Pharmaceuticals (Alexion Pharmaceuticals) COGS-to-Revenue : 0.08 (As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals COGS-to-Revenue?

Alexion Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2021 was $125 Mil. Its Revenue for the three months ended in Mar. 2021 was $1,637 Mil.

Alexion Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2021 was 0.08.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Alexion Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2021 was 92.34%.

Alexion Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Alexion Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals COGS-to-Revenue Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

COGS-to-Revenue

Get a 7-Day Free Trial

0.08

0.13

0.09

0.08

0.09

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
COGS-to-Revenue	Get a 7-Day Free Trial															0.08	0.10	0.09	0.10	0.08

Alexion Pharmaceuticals COGS-to-Revenue Calculation

Alexion Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2020 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	553.5	/	6069.9
	=	0.09

Alexion Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	125.4	/	1636.5
	=	0.08

Alexion Pharmaceuticals (NAS:ALXN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Alexion Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2021 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	125.4 / 1636.5
	=	92.34 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Alexion Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974